Accunea says the device assesses organ condition accurately and in real time before kidney transplants. The company says it believes that the device can prevent good organs from going to waste and save lives. 

Accunea claims that RenoSure will reduce strain on health services and improve patient outcomes by using unique technology which is able to monitor multiple biomarkers of kidney function and metabolism. 

This would allow doctors to assess the health of a donated organ and decide whether to use it based on objective data. This would help them to make the difficult decision of whether to go ahead with a transplant in the operating theatre, significantly increasing the number of transplants and preventing organ wastage.